article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

The company is “preparing for clinical development in 2026” across multiple indications, Goutopoulos said. Some of those, including Novartis and Ratio Therapeutics , are also targeting FAP. Actithera has not disclosed which cancers it’s targeting with its therapies.

article thumbnail

Key Trends Drug Developers Need to Know to Succeed

PPD

Small/mid-size participants in particular indicate greater use of DCTs, expecting higher use by 2026. As DCTs become standard across toolkits, there is greater opportunity to implement decentralized approaches when needed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Characterizing Antibody-Drug Conjugates Through Innovative Analytical Solutions

Fierce BioTech

Characterizing Antibody-Drug Conjugates Through Innovative Analytical Solutions scox Fri, 07/11/2025 - 10:15 Tue, 08/19/2025 - 11:00 Resource Type Webinar Mihir Thakar Jingwen Ding, PhD Promotion End Fri, 01/16/2026 - 17:21 Antibody-Drug Conjugates (ADCs) are a powerful and promising treatment options for patients.

article thumbnail

NGS is evolving: collaboration and tech lead the way

Drug Target Review

Next generation Sequencing Market Size, Share | 2022 – 2026 | MarketsandMarkets [Internet]. This collective approach not only streamlines workflows and reduces costs but also paves the way for scalable, future-ready solutions that are reshaping the landscape of genomics research. References: 1. www.marketsandmarkets.com. Biospace.com.

RNA
article thumbnail

Roche’s NXT007 Shows Early Promise for Normalising Clotting in Haemophilia A

The Pharma Data

The company has announced plans for three global Phase III clinical trials beginning in 2026. A Roadmap to Phase III and Beyond With these encouraging early results in hand, Roche is now preparing to launch a comprehensive Phase III development program for NXT007. This planned comparative study will be a crucial milestone.

article thumbnail

Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

The Pharma Data

Furthermore, Intellia plans to submit a biologics license application (BLA) in 2026 in support of a potential U.S. This data further highlights the strong value we believe this approach can bring to patients, physicians, and payers.”

article thumbnail

Novo Nordisk: Phase 3 Data Shows Mim8 Well-Tolerated After Switch from Emicizumab in Hemophilia A

The Pharma Data

Additional trial results are expected to be presented at upcoming medical conferences and published in peer-reviewed journals throughout 2025 and 2026. Novo Nordisk has stated its intention to submit Mim8 for regulatory approval in 2025, contingent on data from the broader FRONTIER program.